Format

Send to

Choose Destination
Trans R Soc Trop Med Hyg. 2015 Jul;109(7):423-4. doi: 10.1093/trstmh/trv039. Epub 2015 Jun 4.

Development of Leishmania vaccines in the era of visceral leishmaniasis elimination.

Author information

1
QIMR Berghofer, Brisbane, Australia Christian.Engwerda@qimr.edu.au.
2
Department of Microbiology and Immunology, McGill University, Montreal, Canada.

Abstract

A visceral leishmaniasis (VL) elimination target set for the Indian subcontinent in 2005 is being met in many endemic areas without a vaccine. This begs a question: is a VL vaccine needed if elimination targets can be met with current control programs? Here, we argue that a vaccine will be critical if the success of recent VL control efforts are to be sustained. However, not only do we require a safe and effective vaccine, but we also need to know how this should be used for maximum impact. In particular, identifying appropriate target populations to vaccinate will be crucial.

PMID:
26048873
DOI:
10.1093/trstmh/trv039
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center